Literature DB >> 7437261

A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.

E Perucca, A Hedges, K A Makki, A Richens.   

Abstract

1 The disposition kinetics of lignocaine and antipyrine were compared in eight normal subjects and in eleven patients receiving chronic therapy with antiepileptic drugs. The urinary excretion of D-glucaric acid (D-GA) was measured in 16 subjects. 2 In patients treated with antiepileptic drugs antipyrine clearance and D-GA excretion were significantly increased, whereas lignocaine biovailability was significantly reduced. 3 When all the subjects included in the study were considered, a significant positive correlation could be found between the apparent oral clearance of lignocaine (Dose/area under the blood concentration curve) and both antipyrine clearance (r = 0.73) and D-GA excretion (r = 0.74). 4 When normal subjects and epileptic patients were considered separately, a significant positive correlation could be confirmed between the apparent oral clearance of lignocaine and both antipyrine clearance (r = 0.71) and D-GA excretion (r = 0.76) in normal subjects, and between antipyrine clearance and D-GA excretion (r = 0.75) in epileptic patients. 5 These results suggest that the reduction of the oral availability of lignocaine in epileptic patients is secondary to induction of first-pass metabolism of the latter drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437261      PMCID: PMC1430159          DOI: 10.1111/j.1365-2125.1980.tb01794.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

Review 3.  Clinical implications of enzyme induction.

Authors:  A Breckenridge
Journal:  Basic Life Sci       Date:  1975

4.  The comparative enzyme-inducing properties of antiepileptic drugs [proceedings].

Authors:  E Perucca; A Hedges; K Makki; S Hebdige; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

5.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

6.  Genetic control of drug levels and of the induction of drug-metabolizing enzymes in man: individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism.

Authors:  E S Vesell; G T Passananti; F E Greene; J G Page
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

7.  Genetic control of dicumarol levels in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

8.  Interactions of benzodiazepines with warfarin.

Authors:  M Orme; A Breckenridge; R V Brooks
Journal:  Br Med J       Date:  1972-09-09

9.  Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model.

Authors:  N Benowitz; F P Forsyth; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

10.  Comparative metabolism of benzo[a]pyrene and drugs in human liver.

Authors:  J Kapitulnik; P J Popper; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

View more
  8 in total

1.  The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans.

Authors:  C Reichel; T Skodra; A Nacke; U Spengler; T Sauerbruch
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 2.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

3.  Pharmacokinetics of antipyrine in epileptic patients.

Authors:  E M Rimmer; P A Routledge; L M Tsanaclis; A Richens
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Antipyrine kinetics in liver disease and liver transplantation.

Authors:  M U Mehta; R Venkataramanan; G J Burckart; R J Ptachcinski; S L Yang; J A Gray; D H Van Thiel; T E Starzl
Journal:  Clin Pharmacol Ther       Date:  1986-04       Impact factor: 6.875

5.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.

Authors:  E Perucca; M Ruprah; A Richens; B K Park; D J Betteridge; A M Hedges
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

6.  The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics.

Authors:  T K Daneshmend; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.